Hepatitis C New Zealand

June 2, 2010

New Zealand Hepatitis C Croydon Day Surgery

NZ Ministry of Health Press Release

2 June 2010

55 Women at Risk of Hep C being Traced

New Zealand and Australian health authorities are tracing 55 New Zealand women who visited a private medical clinic in Australia between 1 January 2006 and 7 December 2009 who may be at risk of having contracted Hepatitis C.

Ministry of Health Deputy Director of Public Health Dr Fran McGrath says Australian authorities identified the link between a cluster of hepatitis C cases and a private medical centre in the State of Victoria, Australia in April and are now investigating how this happened.

There is a police investigation in Victoria and media reports of legal action in Australia being planned.

“The Department of Health in Victoria, has taken responsibility for tracing, directly contacting and confidentially informing all 3,500 women concerned, including the 55 affected women giving a New Zealand address.”

The Department began contacting the New Zealanders yesterday as they worked through the 3500 women being traced. Around 1000 Australian women have been contacted and 746 tested.

Of those tested 44 have been found to have hepatitis C, around half of whom have had their infection linked to the private medical centre.

Because of the difficulties involved in tracing the women, the Ministry of Health will be working more closely with its Victorian counterpart in helping trace the New Zealand women concerned.

New Zealand women who had procedures at the Croydon Day Surgery in Croydon, Victoria from 1 January 2006 to 7 December 2009 can call Healthline in New Zealand and be transferred free of charge to a confidential Australian hepatitis line for further information.

“This is a sensitive and potentially distressing situation and the Ministry of Health here and health authorities in Australia are being careful to protect the privacy and confidentiality of the women involved”, Dr McGrath says.

Specialist staff in District Health Boards in New Zealand are on standby to offer blood testing, follow-up, support and treatment if necessary.

“Based on the results of women tested to date approximately 5% of women treated at the clinic may have contracted Hepatitis C. Based on this information we estimate that up to 3 New Zealand women may test positive.”

Any woman who has received treatment in a Melbourne private clinic in the four years from 2006 to 2009 should contact (New Zealand ) Healthline 0800 611 116 for advice.

Hepatitis C is a blood-borne virus that causes inflammation of the liver and which can have serious complications.

For more information contact Peter Abernethy, Media Relations Manager, 021 366 111

Further information can be found at the Victoria Department of Health website http://www.health.vic.gov.au/chiefhealthofficer/alerts/

Press release ends

Hepatitis C cases linked to doctor grows


AAP

The number of women infected with Hepatitis C after being treated by a Melbourne doctor has grown to 44 and is rising.

Another 32 women have tested positive to the infection after being treated by James Latham Peters, an anaesthetist at a Croydon abortion clinic, the Department of Human Services (DHS) revealed on Monday.

That number is certain to grow and the DHS has urged any women who have had abortions and been treated by Dr Peters at the Croydon Day Surgery to contact them.

The number of women infected with Hepatitis C after being treated by a Melbourne doctor has grown to 44 and is rising.

Another 32 women have tested positive to the infection after being treated by James Latham Peters, an anaesthetist at a Croydon abortion clinic, the Department of Human Services (DHS) revealed on Monday.

That number is certain to grow and the DHS has urged any women who have had abortions and been treated by Dr Peters at the Croydon Day Surgery to contact them.

More than 1100 women treated by Dr Peters since 2008 have been contacted by DHS and told to be tested, with the results of 746 women received showing 32 infection cases, Victoria’s chief health officer Dr John Carnie said.

Dr Carnie and police believe the doctor recklessly and maybe deliberately infected the women by using needles he had contaminated.

“The more cases you find in this instance, it becomes more and more difficult to explain this by any other accidental means,” Dr Carnie told reporters on Monday.

http://news.smh.com.au/breaking-news-national/hepatitis-c-cases-linked-to-doctor-grows-20100531-wpuu.html

best of health

www.hcv.org.nz

May 11, 2010

New Zealand World Hepatitis Day, May 19 2010

New Zealand World Hepatitis Day, May 19 2010  update

A couple of events for world Hepatitis month here in New Zealand

Hepatitis Free concert in Latimer Square Christchurch May 22 nd 11 am – 4 pm

The Hepatitis C Resource Centre Te Waipounamu in conjunction with World Hepatitis Day  proudly present a free concert in Latimer Square Christchurch Saturday May 22 nd 11 am – 4 pm info stalls, Sausage Sizzle,bouncy castle, byo picnic

Lots of Bands Squirm , Dialtones , Mynor Starr ,Anthesiac, Magic Eye, Anthesiac,Papanui High School Jazz combo, ChisnallwoodIntermediate Bands Vivid Distortion, Chain Reaction, Closing Time, 1.5l sprite bottle, DJ Detox Damage.

hepc-gigposter2010
further details contact Hepatitis C Resource Centre Christchurch phone 3663608  email hcv @xtra.co.nz

Opening of the new Hepatitis C Resource Otago Centre office May 19 2010

A great day out in Christchurch and if you make it to the event watch out for  Hepatitis C Resource Centre Dunedin phlebotimist Heath in his band,  Heath will be back in Dunedin on 19 May for the opening of the new Hepatitis C Resource Centre office in Dunedin.

further details contact Heath and  Allison at Otago  Hepatitis C Resource Centre hepcotago @xtra.co.nz

The past month has seen a lead up campaign of  one in twelve hepatitis  awareness ads played nationally on TV 3

best of health

www.hcv.org.nz

May 7, 2010

New Zealand Hepatitis C Blog May 2010

New Zealand Hepatitis C Blog May 2010

World Hepatitis Day, May 19, aims to raise global awareness of hepatitis B and hepatitis C and encourage prevention, diagnosis and treatment.
World Hepatitis Day is led by the World Hepatitis Alliance, which represents 200 patients groups and organizations
http://www.worldhepatitisday.org/en/Home.aspx

The Hepatitis Comics

Have a laugh with Lucinda K. Porter ‘s blog The Hepatitis Comics. Lucinda is hepatitis C positive and positively believes in the power of humour.

http://hepatitiscomics.blogspot.com/

Medical transmission of Hepatitis C from Australia

VICTORIANS worried about their contact with Dr James Latham Peters over the past four years should contact health authorities - not just patients of the doctor in 2008 and 2009, as first stated last week.

A spokesman for the Department of Health last night confirmed that Dr Peters had worked at Croydon Day Surgery - the clinic where he allegedly infected 12 patients with his own strain of hepatitis C - since 2006.

On Friday, Victoria’s chief health officer, Dr John Carnie, said the infected patients had visited the clinic between June 2008 and December last year, and that patients worried about their contact with him at the Croydon clinic during this period should contact the department.

He said departmental workers were also trying to contact patients they believed to be at risk of contracting the blood-borne virus from him during this 18-month period.

But the department spokesman last night said authorities would also encourage patients who visited Dr Peters at Croydon Day Surgery as far back as 2006 to seek further information from the department if they were worried about the virus.

As of last night, the department had received 830 calls from people with questions about the anaesthetist, who is believed to have been using drugs when he infected patients with his particular strain of the illness.

Last week, Dr Carnie said he referred the matter to police in March because he found it hard to imagine how the transmission of the virus had been accidental.

http://www.theage.com.au/victoria/officials-welcome-hepatitis-c-feedback-20100412-s4dx.html

Being Warehoused

‘Warehoused : when patients elect to wait for the new drugs’
Warehoused : Thought this was interesting about waiting for new treatments, I think you might have to wait extra long for pharmac to fund a new treatment in New Zealand. So maybe prepare to be in your warehouse with hep c for a long time ?

Hepatitis C Patients May Boost Merck, J&J, Vertex

http://www.businessweek.com

By Michelle Fay Cortez and Naomi Kresge

April 19 (Bloomberg) — At Fred Poordad’s bustling hepatitis C clinic in the heart of Los Angeles, one in every five patients receives no treatment. They are waiting for a wave of new drugs, expected in the next 18 months, that may boost their chance at a cure by as much as 10-fold.

They’re just the first among new therapies anticipated in the next five years as companies seek a single pill to cure the infection. Poordad, chief of hepatology at the Liver Disease and Transplant Center at Cedars-Sinai Medical Center in Los Angeles, doesn’t object when his patients elect to wait for the new drugs, a practice known as “warehousing.”

“The warehousing has been going on for the past year or so,” Poordad said. “I think we’ll see a tremendous increase in the volume of patients that are treated. That’s the most exciting thing in the field for a long time.”

The drugs closest to market, Merck’s boceprevir and telaprevir from Vertex and Johnson & Johnson, are protease inhibitors crafted from the technologies that led to discoveries made in the fight against HIV. The new treatments are being tested as additions to current standard treatments. Both drugs work by blocking the action of the protease enzyme the hepatitis virus needs to replicate, directly stopping it from spreading.

Warehoused better than a wallet biopsy………….

Telaprevir, has had a trial here in NZ recently, with another trial coming soon.

Adding the investigational drug telaprevir to standard treatment for hepatitis C infection cures about half the patients willing to give therapy a second try. That compares to a cure rate of just 14 percent among those who were re-treated with the standard regimen, according to researchers at Duke Clinical Research Institute.

http://www.youtube.com/watch?v=qwKJQgkdJ2s&feature=player_embedded

Happy Hepatitis month

best of Health

www.hcv.org.nz

April 8, 2010

April Hepatitis C New Zealand Blog

April Hepatitis C New Zealand Blog

How many People are treated for Hepatitis C in New Zealand ?

Someone asked me how many people in New Zealand get treated each year for Hepatitis C in  New Zealand.   I  hadn’t thought about that for a while and it would be nice to think New Zealand are treating more people now that three years ago but apparently not. New Zealand has treated around 400 people per year for Hepatitis C  each year for the last three years. There has been no increase in the numbers treated .

Scotland Hepatitis C

In Scotland a country of comparable size to New Zealand’s the Scottish government have set a goal of treating 2000  extra Hepatitis C patients per year.

New Zealand needs this kind of evidence based national goal to increase the numbers of people being treated.

Scotland Progress to date includes:

* Increasing the number of people treated for hepatitis C. NHS boards will treat around 800 new patients for Hep C in 2009-2010, compared with around 400 in 2007-08

* Significant infrastructure and service development for Hepatitis C treatment, care and support to increase treatment numbers further

* A Hepatitis C Managed Care Network (MCN) within each board area, made up of relevant specialists

* A learning and development lead at each health board to co-ordinate training for professionals who deal with people who have, or may have, the virus

http://www.scotland.gov.uk/News/Releases/2010/03/08094128

I found it interesting that

“Although most people contract hepatitis C through injecting drug use, 8 in 10 people currently infected are not currently injecting drugs.”

Scottish Public Health Minister Shona Robison

Do Needle-Exchange Programs Really Work?

A review of the evidence on the effectiveness of harm reduction interventions involving the provision of sterile injecting equipment in the prevention of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) transmission among injecting drug users (IDUs). The interventions assessed were needle and syringe programmes (NSP), alternative modes of needle/syringe provision (pharmacies, vending machines and outreach) and the provision of injecting equipment other than needles/syringes.

http://www.thebody.com/content/news/art55845.html

“The main public health implications of the findings are that a higher level of coverage of interventions, including [NSPs], is likely required to reduce blood-borne virus transmission,” said Palmateer.

http://www.thebody.com/content/news/art55845.html

More evidence is emerging of the role  your genes play in the success of treatment for Hepatitis C

Duke University has been at the fore front of this research

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

It is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African ancestry. In addition to limited efficacy, treatment is often poorly tolerated because of side effects that prevent some patients from completing therapy. For these reasons, identification of the determinants of response to treatment is a high priority.

http://www.nature.com/nature/journal/v461/n7262/full/nature08309.html

Dr. Andri Rauch discusses his manuscript Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-wide Association Study.

A Facebook  page for Hepatitis C New Zealand Peer Support Project

We  www.hcv.org.nz  “a community of people with Hepatitis C trying to help other people who are affected by Hepatitis C.” have a face book page now you can  check it out here.

http://www.facebook.com/pages/Hepatitis-C-New-Zealand/99254558387

Best of Health www.hcv.org.nz

March 8, 2010

Hepatitis C New Zealand Blog March 2010

Hepatitis C conference  Whakatane 2010

Past Failures and New Solutions in Hepatitis B and C control in New Zealand and the Asia Pacific region
Tariana Turia - NZ Viral Hepatitis Conference 2010

Tuatahi me mihi atu ki te mana whenua. Tena koutou o Mataatua waka. Tena hoki koutou o nga mata waka kua whakarauika nei i raro i te karanga o te ra

Tena koutou i runga i te rangimarie. Tena koutou i runga i nga maharatanga mo ratou kua wheturangitia.

No reira, tena tatou katoa

I want to thank the Hepatitis Foundation of New Zealand for the honour of being invited to open this third New Zealand Viral Hepatitis Conference.

I acknowledge the local people of this rohe, and I thank them for their generosity in hosting us here in Whakatane.

I extend a particular welcome to our international guests:

* Professor Mitchell Shiffman from the United States;
* Professor Andrew Lloyd from Australia;
* Dr Morris Sherman from Canada and
* Dr James Fung from Hong Kong.

While both Hepatitis B and C viruses are notifiable conditions under the Health Act, it is only cases of acute infection which require to be notified to the Medical Officer of Health.

Alongside with the lack of awareness that comes from being asymptomatic; people with hepatitis may experience stigma and discrimination which compounds the problems of living with the virus.

So the call to do better is an important one.

We must continue to raise awareness, leading to increased testing and diagnosis.
Well spoken words from Tariana Turia

Life after liver transplant

Hi, This is my first post of my Video Diary following my Liver Transplant and my continued fight against my Hepatitis C infection/virus. Just a quick one to saay hello - I’ve never done video before and so let’s hope for all our sakes that I get better at it soon!

Please check out my blog: http://www.ianquill.blogspot.com - Thanks for watching…. Ian Quill

Hepatitis C Drug Trails NZ March 2010

Four drug trials for Hepatitis C in New Zealand at the moment (March 2010)
http://clinicaltrials.gov/ct2/results?term=hepatitis+c+New+zealand&recr=Open
1, TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

2,  A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

3, Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive

4, Antiviral Activity of AZD7295 in HCV Carriers

Doctor  Magdalena Harris

thesis is available online now

Negotiating the pull of the normal: embodied narratives of living with hepatitis C in New Zealand and Australia (2010)
Harris, Magdalena , National Centre In HIV Social Research, Faculty Of Arts & Social Sciences, UNSW
My status as a person living with hepatitis C informed all aspects of this research project; I therefore also include my own experiences, foregrounding researcher reflexivity and the co-constructed nature of the interview process.

“ My aims are both practical and theoretical. On a practical level I explore the experiences of people living with hepatitis C in order to inform recommendations for policy, research and practice, while also working to elucidate and employ an approach that allows for an analysis of the ill body as a lived experiencing agent, located in a substantive web of connections whereby discourse, corporeality and sociality, inform and mediate one another. To this end I employ a “political phenomenology” influenced by phenomenological and poststructuralist theoretical approaches. The central, previously under-researched, issues that arose in participants’ narratives structure the chapter outline, with results chapters focusing on participants’ experiences of diagnosis, living with hepatitis C, stigma, support group membership, alcohol use, and hepatitis C treatment.

For many participants, it was found that living with hepatitis C was a liminal experience where distinctions between what it was to be healthy or ill were not clear-cut. Indeed, many of the participants’ narratives exposed the inadequacy of Western binary categorisations to speak to their experiences of living with hepatitis C. Throughout this thesis it can be seen that the meanings that participants ascribed to health, illness, and their hepatitis C were fluid and contextual, informed by the interplay of corporeality and discourse. From this interplay comes the ability to speak into the gaps of dominant discourses, creating the potential for the disruption, or subtle realignment, of normative ways of knowing. “
Download  your copy here
http://unsworks.unsw.edu.au/vital/access/manager/Repository/unsworks:7899

Congratulations  Dr Harris from all your peers.

The best of health
www.hcv.org.nz

January 30, 2010

Hepatitis C New Zealand blog January 2010 New Zealand Viral Hepatitis Whakatane 2010

Hepatitis C New Zealand blog January 2010 New Zealand Viral Hepatitis Whakatane 2010

New Zealand Viral Hepatitis 3rd NZ Conference Whakatane 2010

Friday 05 March – Saturday 06 March 2010
War Memorial Complex, Whakatane, New Zealand

Invited Speakers: Professor Mitchell Shiffman, USA

Professor Andrew Lloyd, Australia

Dr Morris Sherman, Canada

Dr James Fung, Hong Kong

Around half the conference will  be about hepatitis B and the other half hepatitis C

With topics such as

Relevance of viral  load; is it a predictor to HCC?  James Fung

Multidisciplinary approach of HCC in NZ  John McCall or Adam Bartlet

Therapies available for patients with HCC in NZ Catherine Stedman

State of the Art Lecture

Optimisation of Outcomes with current standard-of-care” (on use of baseline and
on-treatment responses (RVR, EVR) to individualiase therapy, weight-based RBV).
What’s next – direct acting antivirals (DAAs )Mitch Shiffman

HCV in Correctional Facilities

HCV prevention, treatment and follow-up in prison populations Andrew Lloyd

HCV in NZ correctional facilities Frank Weilert

NZ model in an Auckland prison Steve Gerred

Difficult-to-treat patients

State of Art Lecture
“Approaches to non-responders – retreatment, induction dosing IFN,
higher dosing RBV, maintenance therapy – do they work”  Mitch Shiffman

Alternative therapies for HCV

Is there alternative therapies for HCV treatment and do they work? TBA;   College of natural therapies

Middlemore audit of patients taking alternative therapy Jacinda Ryan

Hepatotoxic therapies Sarah Fitt

Debate: Should there be a national register for chronic HBV & HCV?

You can find out more about the conference at the hepatitis foundation of New Zealand Website here

http://www.hepfoundation.org.nz/conferencep.html

and register here

http://www.hepfoundation.org.nz/RegistrationForm2010.pdf

Our invite must have got lost in the mail and our budget of zero precludes travel. The joys of the peer based NGO.

New Zealand hep c news letter

Got my first email copy of the New Zealand hep c news letter , a joint effort by the Auckland Christchurch and Dunedin Hepatitis C Resources centres.

Well actually I accidentally deleted it so if you want to check it out Hepatitis C resource centre  0800 224372 (0800 22 HEPC)

A viral hepatitis testing pilot project in 19 pharmacies across the country has found a hepatitis B or C positive patient in every 6 tests conducted.

I mentioned this chemist based anonymous testing for hepatitis at English pharmacies a while back; the results of the trial have been interesting

19 pharmacies in 5 PCT areas offered free, on-demand hepatitis B and C dried blood spot tests to clients who had been at risk of contracting viral hepatitis as part of a 3-month pilot project organised by The Hepatitis C Trust. Across the pharmacies a total of 234 tests were conducted, diagnosing 35 people with hepatitis C (15% of tests) and 4 people with hepatitis B (2% of tests). This is a far higher proportion of hepatitis C positive diagnoses than found in GP surgeries, where 4% of tests find positive hepatitis C patients and 2% of tests find hepatitis B patients.

Dev Dalvar from D R Pharmacy in Sandwell PCT commented on the pilot: “Offering hepatitis B and C tests in my pharmacy has been a huge benefit to the local community. The people diagnosed will now be able to access potentially life-saving treatment and many customers are more aware about the viruses and risk factors.

Charles Gore, Chief Executive of The Hepatitis C Trust said: “It is a tragedy that increasing numbers of people with hepatitis C are dying, often because they have been living with the hepatitis B or C undiagnosed for years, even decades. There are at least 100,000 people living with the hepatitis C unawares but only 8,000 people were diagnosed last year. We desperately need a new approach to testing that will find the undiagnosed patients and this pilot study shows pharmacy testing could be just what is needed.

A series of Hepatitis C videos from the Harm reduction works

HIV, hepatitis C and injecting drug use, part 2: The sharing of injecting equipment

Best of health for 2010

www.hcv.org.nz

November 3, 2009

New Zealand Hepatitis C Blog The good news

New Zealand Hepatitis C Blog The good news

The Good News about Coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease
progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).
The study found that patients with hepatitis C-related bridging fibrosis or cirrhosis who did not respond to standard disease treatment benefited
from increased coffee intake. An effect on liver disease was not observed in patients who drank black or green tea. Findings of the study appear
in the November issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Three cups a day and a 53% lower risk of progression that has to make coffee a good option for those with hep c.

http://www3.interscience.wiley.com/journal/122511224/abstract?CRETRY=1&SRETRY=0

The Good news for new treatment options  Telaprevir

Good news for People with Genotype one Hepatitis C is the latest results of the new drug telaprevir
Cork, Ireland (October 31, 2009) –Tibotec announced today results of a new study (VX950-C208), which showed that sustained virologic response (SVR)
was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either
every 8 hours or every 12 hours, in combination with standard of care. Telaprevir, an investigational STAT-C (Specifically Targeted Antiviral Therapy for hepatitis C),
is being co-developed by Tibotec in collaboration with Vertex Pharmaceuticals. The study was presented today at the 60th Annual Meeting of the
American Association for the Study of Liver Diseases (The Liver Meeting).

In the phase II study, which enrolled 161 treatment-naïve genotype 1 patients, rates of SVR (defined as undetectable HCV RNA at 24 weeks after completion of treatment)
ranged from 81 to 85 percent in patients treated with the every 8 hour telaprevir-based regimen, and 82 to 83 percent in patients treated with the every twelve hour regimen.
Adverse events (AEs) were similar to those observed in other trials with telaprevir and were mainly haematologic (anaemia) and cutaneous (rash and pruritus) in nature.

For the vast majority of patients, these high SVR rates were obtained with only 24 weeks of total treatment (half the duration of current standard of care).
Total duration of treatment was decided using a criteria based on treatment response. Subjects who achieved undetectable HCV RNA at week 4
(rapid virologic response or RVR) and maintained this through week 20, were allowed to stop all treatment at week 24. Only 18% of subjects were required to continue standard treatment up to week 48.

Source: Johnson & Johnson Services

Good news for me

My post treatment 24 week viral load came back undetectable

testviralload

The Good news from www.womanaloud.co.uk

Had some good feedback from my last Blog post In particular from Tracy  at  http://www.womanaloud.co.uk/index.html A peer among peers.

” I wish you good health and a sharp pen. Raising awareness of hepatitis C is an uphill struggle… but day by day, one step at a time, it is happening. It is interesting to consider that, if we could get over the brain fog ; D, there are enough of us in the world with this condition, to form our own group/religion/club… if 180 million sufferers were all to shout on the same day, at the same time… mmm … I think I’ll put the kettle on. ”

Thanks Tracy great message. Just off to have a cup of tea myself,  maybe  a coffee as it seems that may be better for me.

Best of Health


www.hcv.org.nz

October 8, 2009

Hepatitis C New Zealand A dark and stormy night

Hepatitis C New Zealand  A dark and stormy night

Public Health Champion 2009 awarded by Public Health Association to Canterbury’s Cheryl Brunton

Dr Brunton’s work with hepatitis C began when she investigated an outbreak at Christchurch Prison in 1991. This led to an on-going interest in hepatitis C research and advocacy. She helped establish the Auckland and Christchurch Hep C support groups, was instrumental in founding the Christchurch Hepatitis C Resource Centre and was the inaugural chair of its trust board. She also took part in the development of the first national Hepatitis C Action plan.

“She continues to arrange conferences, workshops and training on Hep C, played a part in the establishment of the Hepatitis C community clinic in Christchurch, and is part of its advisory group.

I applaud any one working to improve things for people with Hepatitis C long my people care and make a difference, thanks Cheryl from everyone affected by Hepatitis  in New Zealand.

http://www.scoop.co.nz/stories/GE0909/S00025.htm

Prime minister with Hepatitis C

The Prime Minister of Mongolia S.Bayar is the first prime minister to publically announce their hepatitis C Status recently, Bayar was reported to have the viral infectious disease of Hepatitis C before he took office of prime minister. He said that the Prime Minister took a holiday of five working days only since he assumed office in November 2007. In Seoul, Lambaa said, Prime Minister Bayar is now receiving “interferon-based therapy”.

New issue Australian  Hep C  Review magazine available online a good read

The new issue of Australian Hep C magazine is available on line it has some interesting articles about hepatitis C but the one that caught my eye was a   article on drug trials for hepatitis c

Available here.

http://hepmagazines.realviewtechnologies.com/

C-een & Heard speakers program

Inviting a speaker to your agency or organisation provides an opportunity to:
•    Hear first hand personal experiences of people living with hepatitis C
•    Challenge the myths and stereotypes about hepatitis C
•    Address discriminatory attitudes in the workplace and elsewhere
•    Provide a holistic view of health (medical, social, personal)
•    Gain insight into the psychosocial issues associated with hepatitis C
•    Enhance existing training & education initiatives with personal perspectives

Maceon is a guy who lives in Sydney and is involved in community-based education and awareness raising in NSW, Australia. He features in a new DVD produced by the Hepatitis C Council of NSW. It contains stories from several different speakers and is used as a facilitation tool used when our Education and Development team conducts sessions outside the Sydney metropolitan region.

Interesting news story from America about the Hepatitis C hazards of the health care system,

Hep C nurse 20 years jail
Added: 28 September 2009
A former hospital surgical technician who may have infected dozens of surgical patients with hepatitis C by stealing their pain medication and swapping back needles tainted by the virus she carried pleaded guilty on Friday to US federal drug charges. Kristen Parker, 26, could have faced up to life in prison on the most serious charges, but accepted a 20-year prison sentence in a plea agreement with federal prosecutors. Ms. Parker admitted guilt to multiple charges of tampering with a consumer product and obtaining a controlled substance by deceit. Twenty-seven patients at two US hospitals where Ms. Parker worked last year and this year, in Denver and Colorado Springs, have tested positive for a strain of hepatitis C and have been linked to her care, according to state health records. Ms. Parker’s lawyer said outside the courthouse that he thought the lesser sentence was warranted in part by his client’s cooperation with health officials and the police since her arrest this summer

I have been impressed with the English web resource  www.harmreductionworks.org.uk

This website supports the harm reduction works campaign materials. The campaign was developed by Exchange Supplies for the National Treatment Agency as part of the implementation of the Department of Health publication Reducing Drug Related Harm: An Action Plan. The plan commits to reducing the burden of illness and death caused by illicit drug use through improved surveillance of service provision, improved delivery of harm reduction services, and information campaigns aimed at drug users and drug service providers.

http://www.harmreductionworks.org.uk/index.html

Harm reduction works  it has some great information on Hepatitis C  I like this video in particular how small is the hepatitis C Virus is.

Best of Health

www.hcv.org.nz

August 23, 2009

Current Clinical Drug Trials for Hepatitis C In New Zealand

New Zealand has up to six different drug trials currently in progress for Hepatitis C.
1    Recruiting     TMC435-TiDP16-C205: A Phase II Study of TMC435 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
Condition:     Hepatitis C
Interventions:     Drug: PegIFNalpha-2a;   Drug: PegIFNalpha-2a;   Drug: Ribavirin PegIFNalpha-2a;   Drug: Ribavirin PegIFNalpha-2a;   Drug: TMC435 TMC435 Placebo;   Drug: TMC435 Ribavirin;   Drug: TMC435 TMC435 Placebo;   Drug: TMC435 Ribavirin;   Drug: PegIFNalpha-2a;   Drug: TMC435 Placebo Ribavirin

2    Recruiting     A Study of Combination Treatment With an HCV Polymerase Inhibitor (Polymerase Inhibitor) and an HCV Protease Inhibitor (RO5190591) in Genotype 1 Chronic Hepatitis C Patients
Condition:     Hepatitis C, Chronic
Interventions:     Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591

3    Recruiting     Safety and Efficacy of MK7009 Administered With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV)
Condition:     Chronic Hepatitis C Virus Infection
Interventions:     Drug: Comparator: Peg-INF;   Drug: Comparator: RBV;   Drug: Comparator: MK7009;;   Drug: Comparator: Placebo.;   Drug: Comparator: MK7009.;   Drug: Comparator: MK7009;   Drug: Comparator: Placebo;;   Drug: Comparator: Peg-INF.;   Drug: Comparator: RBV.

4    Recruiting   Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive
Condition:     Hepatitis C
Intervention:     Drug: clemizole hydrochloride

5    Recruiting     Antiviral Activity of AZD7295 in HCV Carriers
Condition:     Hepatitis C
Interventions:     Drug: AZD7295;   Drug: Placebo

6    Recruiting     Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
Condition:     Hepatitis C
Interventions:     Drug: VCH-222;   Drug: VCH-222;   Drug: VCH-222;   Drug: telaprevir

Interesting to discover so many trials underway in New Zealand and these are just the current ones.  I guess if you want to get on a drug trial you are chosen as opposed to applying in most cases, but its all ways worth asking your medical provider about them.
You can read more detail at this informative site
www.ClinicalTrials.gov

ClinicalTrials.gov United States National Institutes of Health offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions. A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.

When drug trials go Bad

Whenever I think of drug trials I think of guinea pigs and the tragic British drug trials of March 2006, A case of guinea pig beware I guess.
“It was the first time the drug TBN1412, designed to treat conditions such as rheumatoid arthritis and leukaemia, had been tested on humans.
Within hours of taking it on Monday, the six young volunteers had to be admitted to intensive care.
Ms Marshall, 35, whose boyfriend is critically ill, said the normally healthy 28-year-old’s face was so puffed, he “looks like the Elephant Man”.
She said he was completely lifeless, unable even to move an eyelid.
“They just keep saying he’s very, very sick and we are doing all we can,” she added. “

Such clinical trials were essential for the development of new and better treatments

The Medical Research Council said that while it was “an unfortunate and extremely rare event”, such clinical trials were essential for the development of new and better treatments.”

http://news.bbc.co.uk/2/hi/uk_news/england/london/4808836.stm

Best of Heath www.hcv.org.nz

August 8, 2009

Strategic Directions for Hepatitis C, New Zealand report HCTAG

Strategic Directions for Hepatitis C,

improving access to and uptake of hepatitis C treatment services.

HCTAG Hepatitis C Treatment Advisory Group
, NZ ministry of health

Thanks to NZ minister of health Hon Tony Ryall for releasing this draft copy

A few points that I found interesting the context for HCV Planning

The 50,000 figure with 1300 new infections per year, and we are treating around 600

“unless annual numbers of HCV positive New Zealanders receiving anti viral therapy  were to increase by % 300”

This would put the treatment numbers ahead of the new infections. At the moment we are going backwards every year with less treated than catching hepatitis C.

The current numbers are a joke, a token effort from The Ministry of health they are doing something just nowhere near enough to make an impact on the epidemic.

The pool of infected is growing every year, I could wear myself saying this, but fortunately this report lays it all out, in a much more logical manner then me.

Will anything change  ? NO .

The Ministry of health  are growing a massive public health disaster and there poor quality decision making and public health policy is growing the epidemic and future heath costs

Other recommendations

Key action areas increasing diagnosis

Key action area 3: Increasing the percentage of all people with HCV who have had the disease diagnosed

Key facts

An estimated 75 percent of the New Zealand population with HCV are unaware that they have the disease.

The major barriers to treatment in New Zealand with HCV infection are that people are unaware of their infection, or that the diagnosis is delayed until the liver disease is advanced, by, which time treatment is less effective. Because most people with HCV infection feel well or only have non-specific symptoms, early diagnosis requires targeted testing of all people who are at risk of previous exposure to HCV

• The largest undiagnosed pool of people with HCV are likely to be those aged 40-60 years old, who were infected 25-40 years ago, who at that time occasionally or even  once) injected illicit drugs, but went on to lead ‘conventional  Iives’.

This report should have been released months ago and the country can’t afford to wait to implement improvements. Absolute BS that it doesn’t in clued a implementation plan.

Its’ another reasonable report onHepatitis c in New Zealand it is a shame it will never be acted on and people will die and they will die increasingly in large numbers and they will die utterly preventable deaths. unless there is a significant increase in testing, diagnosis and treatment the number of people with end-stage liver disease – that is decompensated cirrhosis and liver cancer – will continue to increase . We are looking at: unnecessary death.

Draft copy released under OIA 29 July 09

http://www.hcv.org.nz/hepatitiscstrategynz.pdf (3 mgb file)

Meanwhile in England Hepatitis C out of control

undiagnosed; too few of those diagnosed are receiving the recommended treatment; and there are worrying regional variations in hepatitis C healthcare and delivery of treatment across the country. Of particular concern is the number of new infections each year – more than five times the number of people being successfully treated – indicating that prevention methods are not working. Clearly, the management of hepatitis C is out of control.

http://www.hepcoutofcontrol.org.uk/home.html

Hepatitis C is not slowing down in New Zealand it’s growing exponentially

RECENT TRENDS IN ILLEGAL DRUG USE IN NEW ZEALAND, 2006

a frightening reality vividly evident in this report

http://www.ndp.govt.nz/moh.nsf/pagescm/1109/$File/idms-2006-final-report-v2.pdf

“Forty-six percent of the frequent drug users had used injection equipment

after someone else in the past six months”

15.7 Summary of injecting behaviour

Forty-six percent of the frequent drug users had used injection equipment after someone else in

the past six months

Thirty-five percent of the frequent drug users had not always used a new sterile needle and

syringe when injecting drugs in the previous six months

The prevention effort of needle exchanges may have slowed the epidemic but even that seems questionable with behavior like above, the ongoing failure to address the problem is costing New Zealand dearly and is going to continue unless something is done.

Increase prevention efforts audit needle exchanges to optimise their services.

Anonymous community pharmacy blood testing for hep C  to try and reach the %75 of New Zealanders who are undiagnosed.

Show some leadership Ministry of Health and follow through invest in testing diagnosis and treatment.

best of health

www.hcv.org.nz

Older Posts »

Powered by WordPress